Best Biotech podcasts (updated May 27, 2015). Technological applications in biology.
The Stem Cell Podcast is hosted by Christopher Fasano PhD and Yosif Ganat PhD and is dedicated to the field of stem cells. Possible cures, therapies and breakthroughs will be discussed including featured interviews with pioneering stem cell scientists.
The Bio Report podcast, hosted by veteran journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.
The CHI Podcasts are produced by the Cambridge Healthtech Institute and offer in-depth interviews with research and business leaders from many facets of biotechnology.
A video podcast by the American Society for Microbiology that highlights the latest in microbiology, life science and biotechnology news. ASM is composed of over 42,000 scientists and health professionals with the mission to advance the microbial sciences as a vehicle for understanding life processes and to apply and communicate this knowledge for the improvement of health and environmental and economic well-being worldwide. For information about ASM and MicrobeWorld, visit us online at www.microbeworld.org. For questions and/or feedback please email firstname.lastname@example.org.
Nature Biotechnology podcast is a series of conversations with founders, financers and developers from biotech's past, present and future.
Anna Kavanaugh hosts the weekly radio series, "Mad Science: The Genetic Crossroad." The program aims to raise awareness and provide education about genetically modified organisms (GMO), in the world food supply and the practices of the GM biotech industry. The series is dedicated to all issues surrounding GM foods, its usage and ramifications thereof. Anna is a writer, advocate, and founder of the (AKCF) Anna Kavanaugh Charitable Foundation. Her original novel, "The Cord of Callows," now an upcoming expanded trilogy series, is the inspiration for a GMO documentary film entitled, "The Cord of Callows trilogy: Fact Behind the Fiction. Fear Behind the Fact."
Listen to a Pharma Show podcast, which focuses on providing professionals in the pharmaceutical industry with up-to-the-minute information and insights from the experts.
Welcome everybody to Episode 45, be sure to visit stemcellpodcast.com for current and past episodes and to sign up for our newsletter. We begin as always with our Science Roundup sponsored by Thermo Fisher. In this episode, we discuss topics ranging from stem cell controversy still with Gordie Howe, does GDF11 really make you young, making morphine in yeast, restoring brain plasticity in mice, positive results from a RPE clinical trial for AMD, spreading of stem cell tourism and now FDA steps in, and more. Then we bring on Alex Hannay, product manager at Thermo Fisher to talk about the process of differentiation from pluripotent stem cells and new products that could help. Check out www.lifetechnologies.com/differentiation for more info. We then finish off the show with a rant on convenience fees. Enjoy! Below are all of the papers mentioned on the show. We are working on a way to categorize all of the research papers we mention and possibly even provide audio summaries. Enter in your name...
A recent article in Nature Chemical Biology that shows it is possible to convert sugar into morphine with genetically engineered yeast has sparked public attention over the potential illicit use of the technology and the need for regulation. The work, though, also opens up significant possibilities for producing a wide range of drugs and the discovery of new ones to treat everything from cancer to infectious diseases. We spoke John Dueber, assistant professor of bioengineering at the University of California, Berkeley and one of the authors of the study, about the work, its implications, and what role biologists need to play in regulating themselves.
Universities are moving away from a passive approach to technology transfer to engage with industry in new partnerships, put a greater emphasis on translational research, and nurturing technologies so they can give rise to new products and companies. We spoke to Eric Tomlinson, Chief innovation officer of Wake Forest Baptist Medical Center, about these changes, the approach Wake Forest is taking, and how it is forging new relationships with industry and the regional economy.
Amid Zand interviews Dr. Patrick Hurban of Expression Analysis, a Quintiles Company on 30 April, 2015. Dr. Hurban will be speaking at the Knowledge Foundation & Cambridge Healthtech Institute’s Ninth International Sample Prep Technologies, June 25-26, in Bethesda, MD. His talk will examine use of NGS assays to compare results obtained from matched formalin-fixed and frozen tissue specimens. For more information visit http://www.SamplePrepConference.com/
Welcome everybody to Episode 44, be sure to visit stemcellpodcast.com for current and past episodes and to subscribe to our newsletter. We begin as always with our Science Roundup sponsored by Thermo Fisher. In this episode we discuss topics ranging from a chemical in vegetables that can destroy cancer stem cells, chewing gum to prevent signing a song over and over, the first report of germ line gene editing in human embryo, neuronal hyperactivity and neutral stem cells, and the discovery of a new pluripotent stem cell. The second half of the show comes live from The Next-Gen Stem Cell Conference in Saratoga NY, where we interview 4 scientists about their work and conference experience. We then finish off the show with a rant about salt and pepper shakers. Enjoy! Below are all of the papers mentioned on the show. We are working on a way to categorize all of the research papers we mention and possibly even provide audio summaries. Enter in your name and e-mail address below, and we will...
With the mapping of the human microbiome, a new understanding is emerging of the complex relationship between the microorganisms that live in the human gut, skin, and elsewhere on the body, and the role they play both in disease and in maintaining health. Along with growing concerns about drug resistant bacteria, this is giving rise to opportunities for narrow spectrum antibiotics. We spoke to David Martin, founder and CEO of AvidBiotics, about the problems of antibiotic resistance, the benefits narrow spectrum therapies offer, and how the sequencing of the microbiome is leading to new approaches to not only treat infectious diseases, but other diseases not traditional thought of as being driven by microorganisms.
CHI interviews Dr. Gabriela Chiosis, Associate Member and Lab Head of Molecular Pharmacology and Chemistry at Memorial Sloan Kettering Cancer Center about the trends, tools and challenges in developing chaperome-based therapeutics. Discussion questions include: 1. How have you seen this field evolve over the past few years? 2. Can you share with us what we have learned from discovery and clinical efforts thus far? 3. What tools have recently been developed, including those from your lab, that are currently advancing drug discovery in this space? 4. What are the remaining challenges surrounding drug discovery and development in this space? What has hindered FDA approvals? 5. You are giving a lecture during the upcoming Chemical Biology for Target Validation meeting, June 10-11 in Boston – part of the World Pharma Congress 2015. What do you hope to convey to attendees during your lecture? 6. Where do you see the greatest opportunities for continued development? For more information visit...
Dr. Megan Munsie Dr. Mario D’Cruz Welcome everybody to Episode 43, be sure to visit stemcellpodcast.com for current and past episodes and to sign up for our newsletter. We begin as always with our Science Roundup sponsored by Thermo Fisher. In this episode we discuss topics ranging from, a new blood test to predict future breast cancer, chimps used tools to hunt, a new all vegan cheese, drugs that activate endogenous stem cells in the CNS, and more. Then we bring on two guests, Dr. Megan Munsie and Dr. Mario D’Cruz where we discuss the launch of ISSCR’s new website “A Closer Look At Stem Cells” that aims to educate and empower people about stem cell biology and stem cell treatments. We then finish off the show with a rant about driving pet peeves. Below are all of the papers mentioned on the show. We are working on a way to categorize all of the research papers we mention and possibly even provide audio summaries. Enter in your name and e-mail address below, and we will notify you of when...
AgeneBio is developing drugs to treat the pre-dementia stage of Alzheimer’s disease, and other neurological and psychiatric conditions. The company announced encouraging mid-stage results for its lead therapeutic, which works by quieting hyperactivity in the hippocampus portion of the brain, which plays a critical role in the formation of memory. We spoke to Jerry McLaughlin, CEO of AgeneBio about the company’s efforts, why this approach holds promise in delaying the onset of dementia in Alzheimer’s patients, and whether this approach may have implications for other neurological and psychiatric diseases.
In April, the IMS Institute released a new report that U.S. drug spending in 2014 rose 13.1 percent to $373.9 billion, the largest single year increase in spending since 2001. A number of factors drove the increase including the launch of innovative new therapies such as Gilead’s hepatitis C drug Sovaldi. We spoke to Murray Aitken, executive director of IMS Institute for Health Informatics about the new report, the confluence of factors that drove spending higher, and what the outlook is for 2015 and beyond.
AARP, the advocacy group serving people over the age of 50, is taking steps to ensure that digital health technologies best serve its membership. The organization has embarked on an initiative to test the design and functionality of digital health devices for older people and provide feedback to the marketplace. It’s enlisted partners United Healthcare and Pfizer as part of its effort. We spoke to Jeff Makowka, director of thought leadership for AARP, about its efforts, how it’s going about testing devices, and what it hopes to accomplish. We had some technical difficulties on this podcast that were not apparent during the interview. We’ve done our best to clean it up, but you will hear some static early in the recording. We apologize to our listeners and our guest, who we think you’ll find nonetheless interesting.
Welcome everybody to Episode 42, be sure to visit stemcellpodcast.com for current and past episodes and to sign up for our newsletter. We begin as always with our Science Roundup sponsored by Thermo Fisher. In this episode we discuss topics ranging from, genomic analyses of brain tumors, cheap long lasting cell phone batteries, expansion microscopy, feeder stem cell culture may be better than feeder free, hESCs are not being used as gold standard as much anymore, stem cells for dogs, a new RIKEN president, a new possible model for liver disease using iPSCs, etc. Then we bring on neuroscientist and stem cell pioneer Dr. Fred “Rusty” Gage, a professor at the Salk Institute where he discusses past, present, and future work of stem cells and neurogenesis. We then finish off the show with a rant on packing peanuts. Below are all of the papers mentioned on the show. We are working on a way to categorize all of the research papers we mention and possibly even provide audio summaries. Enter in...
A newly discovered archive of documents reveal the sugar industry’s efforts to shape the national research agenda away from the effects of sugar on tooth decay and push for programs to focus on alternatives to reducing consumption. We spoke to Cristin Kearns, a University of California, San Francisco postdoctoral scholar who discovered the papers, about her research, how the agenda of the National Institute of Dental Health became aligned with the sugar industry’s, and how industry can subvert research agendas to protect their economic interests at the expense of public health.
Mark Coflin, Senior Director of Alliance Management at Baxter Bioscience discusses his views on the changes in the alliance management, the evolution of the AM function to meet growing demand, challenges in this space, and Baxter Bioscience’s new start in building world-class alliance management capabilities. For more information visit http://www.Healthtech.com/AMS
The field of immunotherapy is very exciting and holds great promise. This podcast will review limitations of monotherapy, and describe Dr. Curran’s approach for inducing an immune response through combination therapy. He will explain how this approach different from existing approaches and how it uses new strategies to overcome common limitations. Advice will be shared for selecting immunotherapy combinations and review applications emerging in combination therapy that are not possible with monotherapy.
Caroline Bennette of the Group Health Research Institute speaks to CHI on April 3, 2015. Dr. Bennette will be a presenter at TCGC: The Clinical Genome Conference, June 22-24 in San Francisco, CA. Topics include determining the cost effectiveness of returning incidental findings from next-generation sequencing to patients, challenges faced when developing analytic tools and policy models to aid decision-making in oncology and Patient-Centered Outcomes Research at the Group Health Research Institute. For more information visit http://www.ClinicalGenomeConference.com/
Drug resistant bacteria cause 2 million illnesses and approximately 23,000 deaths each year in the United States, according to the U.S. Centers for Disease Control and Prevention. The problem of resistance also limits the ability to treat patients using certain medical procedures, such as chemotherapy, surgery, and organ transplants. Last week, the Obama Administration released its National Action Plan for Combating Antibiotic Resistant Bacteria, a multipronged approach to cut inappropriate use of antibiotics, improve surveillance, and develop new drugs. We spoke to Amanada Jezek, vice president of public policy and government relations at the Infectious Diseases Society of America, about the administration’s plan, whether it offers any new ideas, and what needs to be done to ensure its success.
Elizabeth D. Buttermore of Boston Children's Hospital and Harvard Medical School speaks to CHI on March 27, 2015. Dr. Buttermore will be presenting during the 3D Cellular Models conference at the 2015 World Preclinical Congress, June 10-12 in Boston, MA. Topics include how human-derived neurons enhance preclinical phenotypic screening, heterologous expression systems, translational research and the potential of pain models and peripheral neuropathy research for drug development. Find more at http://www.WorldPharmaCongress.com/
Welcome everybody to Episode 41, be sure to visit stemcellpodcast.com for current and past episodes and to sign up for our newsletter. We begin as always with our Science Roundup sponsored by Thermo Fisher. In this episode we discuss topics ranging from, the c. elegans worm that can detect cancer in urine samples, a new autism gene, germ line genetic modifications, stem cells from sheep for face cream, a new way to make 3D mini-lungs in the dish and a new protein involved in making neurons from stem cells. Then we bring on Dr. Eirini Papapetrou, an associate professor at the Icahn School of Medicine at Mt. Sinai where she discusses her work and latest paper on using stem cells to model blood diseases containing a chromosomal deletion. We then finish off the show with a rant on the company refrigerator rules. Below are all of the papers mentioned on the show. We are working on a way to categorize all of the research papers we mention and possibly even provide audio summaries. Enter in your...
ASM's Cultures magazine traveled to Colombia to speak with and film the researchers behind an innovative biotechnology project that is producing exciting results. The international Swiss – Colombian collaborative research team from the University of Lausanne – Switzerland, the Universidad Nacional de Colombia, and the Universidad de la Salle – Utopia campus has been working to create and test novel strains of arbuscular mycorrhizal fungi (AMF) to improve cassava production. AMF forms symbiotic relationships with the majority of the world’s plant species, including cassava and other major food security crops. By colonizing internal structures within the plant and extending its root system, AMF transports nutrients such as phosphate to the plants from inaccessible areas and sources in the soil. In exchange, the plant provides carbon to AMF species that have colonized the plant. The research team’s studies show that, with the inoculation of certain AMF strains, only half of the necessary phosphate...
By email@example.com (American Society for Microbiology)
By firstname.lastname@example.org (American Society for Microbiology)
Adverse events from drugs cost the U.S. healthcare system an estimated $25 billion in 2013, but data from adverse events reporting is generally not factored into payer and provider decisions about what drugs are most cost-effective. The healthcare analytics firm AdverseEvents is trying to change that by turning adverse events data gathered by the U.S. Food and Drug Administration into actionable information. We spoke to Brian Overstreet, CEO of AdverseEvents, about its RxCost offering, why payers and providers rely on mostly pre-approval clinical data in their drug decision making, and why it’s important to consider the broader costs associate with a drug.
Kari Stefansson talks about the founding of deCODE, his love for literature (and his favorite poet), plus his encounter with the tortured chess grandmaster Bobby Fischer.
By email@example.com (Nature Biotechnology)
By firstname.lastname@example.org (Nature Biotechnology)
CHI sits down with Dr. Mike Makrigiorgos of Dana Farber and Brigham to discuss a new COLD-PCR method (temperature tolerant COLD-PCR) that uses targeted re-sequencing to detect mutations as low as .01-.1%. In this podcast, Dr. Makrigiorgos discusses the science behind COLD PCR, gives a preview of his talk at the April cfDNA conference in Lisbon, and discusses the future impact of liquid biopsy.
Tomasz Sablinski believes the drug development process is broken and has sought to reinvent it. His company, Transparency Life Sciences, relies on crowdsourcing to design its clinical trials, makes all of its data public, and employs digital technologies to remotely monitor participants and dramatically reduce the costs of studies. Now, several years into his efforts, we checked in with Sablinski, CEO of Transparency, about the progress he’s made, what barriers his encountered, and whether his success is having any impact on the way other companies are conducting drug development today.
Nathaniel Pearson of the New York Genome Center speaks to CHI on March 17, 2015. Dr. Pearson will be a keynote presenter at TCGC: The Clinical Genome Conference, June 22-24 in San Francisco, CA. Topics include biological and genomic diversity, the evolution of systems over time, the New York Genome Center’s leveraging of citizen data, the value of participatory science on genomic research, applying big data management lessons from other fields to genomics for long-term healthcare and more. For more information visit http://www.ClinicalGenomeConference.com/
James L. Sherley of Asymmetrex (launched in 2013 as “The Adult Stem Cell Technology Center (ASCTC)”) speaks to CHI on March 16, 2015. Dr. Sherley will be presenting during the 3D Cellular Models conference at the 2015 World Preclinical Congress, June 10-12 in Boston, MA. Topics include asymmetric self-renewal of tissue stem cells, p53 regulation, stem cell kinetics dynamics and the dimension of time, incorporating cell turnover into 3D cellular models, and combining computer simulation and primary tissue cell culture for drug toxicity research.
Wow, 40 episodes in the books, and we have another great episode for you. Please make sure you go to StemCellPodcast.com and sign up for our newsletter to get the latest episode and all the paper links emailed directly to you. In today’s episode we start off with our science round up brought to you by Thermo Fisher where we discuss a range of topics including, stem cell research in Oklahoma is now illegal, autism and the link to better cognitive ability, a new gene that regulates mouse fertility, stem cells as a toll to screen drug side effects, making cartilage from stem cells, a new study looking at the genomes of a 1000 autistic people, and what happens to stem cells in the brain as we age. Then we bring on our guest, world-renowned geneticist, Dr. Fred Alt from Harvard Medical School to talk about his latest paper in Nature Biotechnology where he describes a novel method to detect off target effects of gene editing technology. Then we finish off the show with a rant on USB cables. Enjoy...
The biopharmaceutical industry has long been considered immune to the threat of patent trolls, patent holders who seek to monetize the value of a patent through enforcement rather than productive use. But a paper by UC Hastings Robin Feldman and Harvard Fellow Nicholson Price argues that the biopharmaceutical industry should be worried and that steps should be taken now to counter the threat before it blossoms into an industrywide problem. We spoke to Feldman, professor of Law and Director of the Institute for Innovation Law at the UC Hastings College of Law about the study, why the biopharmaceutical industry should be concerned, and what steps can be taken to deter abusive behavior while protecting innovation.
Krista Woodley of Biogen speaks to CHI on March 12, 2015. Ms. Woodley will be presenting during the Cloud Computing and Data Security tracks at Bio-IT World Conference & Expo, April 21-23 in Boston, MA. Topics include IT risk management and regulatory compliance in the life sciences, how the rise of cloud-based computing has altered data security management, compliant cloud computing and more.
A first of its kind study of venture investment in therapeutics by disease area and innovation finds that venture investment following the Great Recession has not yet recovered to the levels seen in the years leading up to the financial crisis. In addition, the study shows great disparities in the level of funding of disease categories and finds that chronic diseases with large patient populations have seen some of the biggest drops in investment. We spoke to Dave Thomas, one of the authors of the study from the Biotechnology Industry Organization, about its findings, where dollars are going and where they are not going, and what effect recent policies may have had in attracting investment to certain areas.
Laura J. van ’t Veer of University of California, San Francisco speaks to CHI on March 4, 2015. Dr. van ‘t Veer will be a keynote presenter at TCGC: The Clinical Genome Conference, June 22-24 in San Francisco, CA. Topics include the genetic makeup of breast cancer tumors and personalized medicine; transdisciplinary research collaborations related to the MammaPrint test; molecular genomic data integration, cancer patient therapy and survival prediction. For more information visit http://www.ClinicalGenomeConference.com/
Hosts: Vincent Racaniello Guests: Maria Julia Marinissen, Edward H. You, and David R. Howell Vincent meets up with Maria, Edward, and David at the ASM Biodefense and Emerging Infections Research meeting to talk about alternative careers for scientists. Links for this episode: ASM Biodefense meeting FBI Biological Countermeasures Unit Office of Policy and Planning Division of Medical Countermeasures Strategy and Requirements Division of International Health Security Don't miss an episode of MicrobeWorld Video. Subscribe for free using iTunes or help support our work by purchasing the MicrobeWorld podcast application for iPhone and Android devices in the iTunes or Android app stores.
By email@example.com (American Society for Microbiology)
By firstname.lastname@example.org (American Society for Microbiology)
John Conley of UNC and Robinson Bradshaw & Hinson speaks to CHI on March 3, 2015. Dr. Conley will be presenting during the IT Infrastructure – Hardware, Software Development, Cloud Computing and Data Security tracks at Bio-IT World Conference & Expo, April 21-23 in Boston, MA. Topics include data security and privacy at large health research institutes vs. smaller biotech companies, plus changes to international data privacy regulations and differences between the U.S. and European Union. Find more at: http://www.Bio-ITWorldExpo.com/
Welcome to another episode of THE Stem Cell Podcast. Thanks everyone for the continued support and be sure to visit stemcellpodcast.com to sign up for our e-newsletter and see all the great resources we have there for everyone. In this week’s episode we start as always with our science round up sponsored by Thermo-Fisher where we discuss some of the most recent science/stem cell news. Some of the topics discussed on this episode range from stem cell fraudster teams up with stem cell pioneer, posthumous stem cell publication, the most addicting foods, exposure to peanut butter reduces risk of allergies, an obese mouse model called “blobby” and a rejected stem cell patent case. Then we bring on Dr. Rhonda Newman to talk about her work in trying to figure our a better way to “de-stress” stem cells. Then we finish off the show with a rant about getting a pebble in your shoe. Enjoy! Below are all of the papers mentioned on the show. We are working on a way to categorize all of the research papers...
At the end of January, after nearly a year of hearings, roundtables, and white papers, the House Energy and Commerce Committee’s Subcommittee on Health released a draft of the much anticipated 21st Century Cures Act. The draft, nearly 400 pages long, addresses a broad range of issues in the drug and device development and review process. We spoke to Nick Manetto, principal with the national advisory and advocacy firm FaegreBD, about the legislation, where the points of controversy lay, and whether despite its bipartisan birth political brawling is ahead.
This podcast presents an interview with Dr. John Kellie, an Investigator in the Bioanalytical Sciences and Toxicokinetics group at GlaxoSmithKline, and a speaker in the Characterization of Biotherapeutics meeting at the 11th Annual PEGS Boston. John explains how next-generation analytical technologies are being used to characterize circulating ADC species, and how these findings support the development of safe and effective antibody-drug conjugate therapeutics. To learn more, visit http://www.PEGSummit.com/Biotherapeutics-Characterization
There’s no shortage of data created in the world of healthcare, but harnessing it to improve care and reduce costs remains a challenge. Apervita, backed with $18 million recent venture investment from GE Ventures, Baird Capital, and others is a marketplace for people to buy and sell their healthcare analytics. We spoke to Paul Magelli, CEO of Apervita, about the pressures on healthcare providers today, the challenges to integrating analytics into practice, and how Apervita hopes to change that.
Welcome to another episode of THE Stem Cell Podcast. Thanks everyone for the continued support and be sure to visit stemcellpodcast.com to sign up for our e-newsletter and see all the great resources we have there for everyone. What a great show we have this week featuring awesome new stem cell news and a great interview with a real stem cell “big fish.” We start as always with our science round up sponsored by Thermo-Fisher where we discuss some of the most recent science/stem cell news. Some of the topics discussed on this episode range from approval of a 3 parent gene therapy, stem cells for breast implants, stem cell derived brain cells to repair radiation damage, a rapid HIV test on your iPhone, a detailed bacteria map of NYC, info about tattoos on the ancient iceman, and optogenetics and neurons. Then we bring on world renowned stem cell researcher Dr. Lorenz Studer to talk about his work, latest paper, and progress towards a new therapy for Parkinson’s Disease. Then all three of...
President Obama unveiled the details of his $215 million precision medicine initiative, the centerpiece of which is a 1 million person study that seeks to correlate genetic data, with health records, lifestyle information, and more to better understanding wellness and disease and fuel the development of new therapies. We spoke to Amy Miller, executive vice president of The Personalized Medicine Coalition, about the initiative, if the funding for it will match its ambition, and whether concerns about privacy will stand as a barrier to its success.
Mimi Langley interviews Dr. Jon Lai, Associate Professor at Albert Einstein College of Medicine on February 4. Dr. Lai will be speaking during the Phage & Yeast Display conference at PEGS China Summit, taking place March 31-April 2 in Shanghai, China.
CAR-T cell immunotherapies seek to harness the body’s immune system to fight tumor cells. The promise of this new class of therapies has ignited investor’s imaginations, but a new report from EP Vantage argues that the enthusiasm that has driven valuations of CAR-T companies should be tempered by an eye towards the risks. We spoke to Jacob Plieth, report author and senior reporter for EP Vantage, about the promise of these therapies, what we know about their safety and efficacy, and why the muddy intellectual property landscape is a concern.
Dave Peterson of Kaiser Permanente speaks to CHI on February 3, 2015. Mr. Peterson will be a panelist during the IT Infrastructure – Hardware, Software Development, Cloud Computing and Data Security tracks at Bio-IT World Conference & Expo, April 21-23 in Boston, MA. Topics include IT compliance and managing vendor-related data security risks, the value of regulations alongside technological innovation, balancing patient privacy with biological research needs, reporting on controls effectiveness for service providers and more. http://www.Bio-ITWorldExpo.com/
Welcome everyone to episode 37! Be sure to go to www.stemcellpodcast.com for previous episodes and to enter your name and email to sign up for our newsletter. On this episode we begin with our signature Science Roundup sponsored by Thermo-Fisher Scientific. In this episode of The Stem Cell Podcast, we discuss papers on a range of topics including making hair from stem cells, a new Parkinson’s disease trial, measles on the rise, BPA affects sperm stem cells, too much salt is bad for your brain, and birth controls link to brain cancer. Then we bring on Dr. Christine Mummery to discuss how stem cells are being used for heart disease. We also discuss the new open access journal Stem Cell Reports. After this we finish with a rant about botched weather forecasts. Below are all of the papers mentioned on the show. We are working on a way to categorize all of the research papers we mention and possibly even provide audio summaries. Enter in your name and e-mail address below, and we will notify...
Investment in biomedical research in the United States is declining at a time when other countries have been increasing their spending. While this is raising concerns about the threats this poses to the nation’s economic competitiveness, a new study in the Journal of the American Medical Association suggests new strategies will be necessary to fund research and development if the clinical value of past investments and opportunities to improve care are to be fully realized. We spoke to study co-author Ray Dorsey, Professor of Neurology and Co-Director of the Center for Human Experimental Therapeutics at the University of Rochester Medical Center, about the findings, what strategies can be employed to reverse the trends, and why new investment alone is not the answer.
David Barton will discuss the new regulations being developed, which have major implications for IVD manufacturers and for laboratory-developed tests. This podcast will give an overview of the proposed new IVD regulation, a timeline for development, and briefly discuss how it will impact IVD manufacturers and clinical labs.
It was an unprecedented year for M&A activity in the life sciences, but even though Big Pharma returned to dealmaking after largely spending 2013 on the sidelines, it’s been unable to close its growth gap through acquisitions. Specialty Pharmaceutical and Big Biotech have been building muscle and key acquisitions that could address growth for Big Pharma continue to be snapped up by competitors. We spoke to Jeff Greene, EY’s Global Life Sciences Transaction Advisory Services Leader, about his firm’s new M&A report, at what point the growing price of assets becomes too rich, and what the outlook is for 2015.
By The Bio Report
By The Bio Report
Carl Feldbaum was the founding president of the Biotechnology Industry Organization (BIO), and he is the current chairman of the Life Sciences Foundation. His podcast conversation with Nature Biotechnology touches on his assistance in prosecuting Watergate, his visit to Saddam Hussein's palace and how he built BIO from the ground up.
By Nature Biotechnology
By Nature Biotechnology
Dr. Mark Gerstein of Yale University speaks to CHI on January 16, 2015. Dr. Gerstein will be a speaker during the Clinical Genomics track at Bio-IT World Conference & Expo, April 21-23, 2015 in Boston, MA. Topics include evolving data science applications to genomics, the utility of networks for biological data analysis and integration, studying non-coding mutations for cancer genomics and personal genomics research, the computational tool FunSeq and more. http://www.bio-itworldexpo.com/
Welcome back for another great episode of the SCP. Be sure to visit www.StemCellPodcast.com and enter your email address in to receive all the show notes and links to all the papers we discuss. We start as always with the science round up brought to you by Thermo Fisher Scientific. In this episode, we discuss the latest and greatest papers ranging from a repurposed over active bladder medication, what stem cell companies to invest in for 2015, a review of the latest iPSC reprograming methods, a new optogenetics study relating to Parkinson’s disease, the sequencing of the oldest mammals genome, and stem cells from the eye to repair damaged corneas. We then talk to Dr. David Piper about disease model tools. Yosif and I then close the show ranting about Parafilm. Enjoy! Below are all of the papers mentioned on the show. We are working on a way to categorize all of the research papers we mention and possibly even provide audio summaries. Enter in your name and e-mail address below, and we will...
It is still a fairly new-recognized and rapidly increasing reality. Gluten intolerance has become a primary health concern for millions of consumers around the world. However, in the face of such an epidemic, the biotech industry is in aggressive pursuit of genetically manipulating a relief for this affliction, one they seek undoubtedly to capitalize on. If brought to fruition, the result of such a genetically engineered response may in actuality cause more grave consequences to consumers than it will provide them help. Revealing the latest research and what it says about gluten intolerance and the dangers involved with GM alternatives currently under development. If you are one of the millions suffering from this affliction, please don't miss out on hearing the important information brought to you in this broadcast.